Camrelizumab vs placebo in combination with chemotherapy as neoadjuvant treatment in patients with early or locally advanced triple-negative breast cancer

JAMA

2024-12-13

(Press-News.org) About The Study: Among patients with early or locally advanced triple-negative breast cancer, the addition of camrelizumab, an anti–PD-1 antibody, to neoadjuvant chemotherapy significantly improved pathological complete response.

Corresponding Authors: To contact the corresponding authors, email Zhi-Ming Shao, MD (zhiminshao@fudan.edu.cn) and Lei Fan, MD (teddyfl@163.com).

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jama.2024.23560)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Media advisory: This study is being presented at the San Antonio Breast Cancer Symposium.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.23560?guestAccessKey=1f9e55e6-3a16-43df-9459-4a0040abc9c0&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=121324

END

ELSE PRESS RELEASES FROM THIS DATE:

Intermittent fasting inhibits hair regeneration in mice

2024-12-13

Intermittent fasting has proven benefits for metabolic health, but a new study shows that it could slow hair growth—at least in mice. Researchers report December 13 in the Cell Press journal Cell that mice subjected to intermittent fasting regimes showed improved metabolic health but slower hair regeneration compared to mice with 24/7 access to food. A similar process might occur in humans, based on a small clinical trial that the team also conducted, but it’s likely to be less severe since humans have a much slower metabolic rate and different hair growth patterns compared to mice. “We don't want to scare people away ...

Changes in adult obesity trends in the US

2024-12-13

About The Study: The findings of this study suggest that body mass index and obesity prevalence in the U.S. decreased in 2023 for the first time in more than a decade. The most notable decrease was in the South, which had the highest observed per capita glucagon-like peptide 1 receptor agonist (GLP-1RA) dispensing rate. However, dispensing does not necessarily mean uptake, and the South also experienced disproportionately high COVID-19 mortality among individuals with obesity. Corresponding Author: To contact the corresponding author, Benjamin Rader, PhD, MPH, email benjamin.rader@childrens.harvard.edu. To ...

Prevalence of post–COVID-19 condition and activity-limiting post–COVID-19 condition among adults

2024-12-13

About The Study: In 2023, among 29,522 respondents to the National Health Interview Survey, a nationally representative household survey, 8.4% of adults in the U.S. reported they ever had post–COVID-19 condition (PCC; also known as long COVID), 3.6% currently had PCC, and 2.3% currently had activity-limiting PCC. Significant differences across all 3 outcomes were observed by sex, sexual orientation, age, race and Hispanic origin, family income, and urbanization. Corresponding Author: To contact the corresponding author, Anjel Vahratian, PhD, MPH, email avahratian@cdc.gov. To access the embargoed study: Visit our For The Media website ...

Scientists innovate breeding strategies to create climate-smart crops

2024-12-13

A recent study has reported a novel breeding strategy to rapidly create climate-smart crops that show higher yield under normal conditions and greatly rescue yield losses under heat stress both in staple grain and vegetable crops. The study, which was published in Cell on 13 December, was conducted by Prof. XU Cao’s team from the Institute of Genetics and Developmental Biology (IGDB) of the Chinese Academy of Sciences. The year 2050 is fast approaching and farm productivity must increase by 60% in order to feed a projected global population of 10 billion. However, current crop production is insufficient and is expected to worsen due to the abiotic-stress burden ...

The genetic basis of fertility, family and longevity

2024-12-13

Led by researchers from the University of Oxford’s Leverhulme Centre for Demographic Science and the University of Iceland, the review explores how genetic variations can explain differences in reproductive health and longevity. The study provides the most comprehensive review of male and female genetic discoveries of reproductive traits to date, and provides new insights into how our DNA affects when we have children, the timing of menopause, and even how that is connected to how long we live. Genes at the heart of reproduction Using the GWAS Catalog, an online database of Genome Wide Association Studies (GWAS), the researchers identified ...

Exposure to remote wildfire smoke drifting across the US linked to increased medical visits for heart and lung problems

2024-12-13

Wildfire smoke has long been known to exacerbate health problems like heart disease, lung conditions, and asthma, but now a new study finds that smoke from these fires can lead to poor health thousands of miles away. Researchers from the University of Maryland Institute for Health Computing (UM-IHC) found that medical visits for heart and lung problems rose by nearly 20 percent during six days in June, 2023, when smoke from Western Canadian wildfires drifted across the country, leading to very poor air quality days in Baltimore and ...

Northwestern University joins Giant Magellan Telescope International Consortium

2024-12-13

PASADENA, CA – December 13, 2024 – The Giant Magellan Telescope announced today that Northwestern University has joined its international consortium to construct the $2.54 billion observatory. Home to the world-renowned Center for Interdisciplinary Exploration and Research in Astrophysics (CIERA) and the newly founded NSF-Simons AI Institute for the Sky (SkAI), Northwestern is at the forefront of advancing astrophysical research. Northwestern researchers will develop and apply cutting-edge artificial intelligence ...

HR-positive, HER2-negative breast cancer patients with high risk of recurrence may benefit from addition of anthracyclines to taxane- based chemotherapy

2024-12-13

SAN ANTONIO – Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy regimens compared with those receiving adjuvant taxane-based chemotherapy regimens alone, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024. “HR-positive, HER2-negative is the most common type of breast cancer in the United States and we frequently need to decide whether or not adjuvant chemotherapy ...

ZEST trial offers insights for using ctDNA to predict breast cancer recurrence

2024-12-13

SAN ANTONIO – The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients positive for ctDNA, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024. As some of the lessons learned from this trial, investigators suggest beginning ctDNA testing during treatment rather than waiting for treatment completion as done in ZEST, and including patients with high- risk ...

Multimodal machine learning model effective at predicting response to CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer patients

2024-12-13

SAN ANTONIO – A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer would have better outcomes from adding CDK4/6 inhibitors to endocrine therapy as first-line treatment, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024. While the use of CDK4/6 inhibitors combined with endocrine therapy have significantly improved outcomes in patients with HR-positive, ...

Camrelizumab vs placebo in combination with chemotherapy as neoadjuvant treatment in patients with early or locally advanced triple-negative breast cancer

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: